Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Choi J, Lee JE, Choi CM, Oh IJ, Lee KY, Jang TW, Lee SH, Kim EY, Park DW, Park SH, Lee SY. Choi J, et al. Among authors: park sh, park dw. Thorac Cancer. 2022 Dec;13(23):3431-3435. doi: 10.1111/1759-7714.14663. Epub 2022 Oct 19. Thorac Cancer. 2022. PMID: 36259253 Free PMC article. Clinical Trial.
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH. Park JH, et al. Among authors: park sh. J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. doi: 10.1007/s00432-021-03527-4. Epub 2021 Feb 1. J Cancer Res Clin Oncol. 2021. PMID: 33523301
Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial.
Kim YH, Ahn SJ, Moon SH, Kim JH, Kim YC, Oh IJ, Park CK, Jeong JU, Yoon MS, Song JY, Suh CO, Cho KH, Park SH. Kim YH, et al. Among authors: park ck, park sh. Int J Radiat Oncol Biol Phys. 2023 Mar 15;115(4):873-885. doi: 10.1016/j.ijrobp.2022.10.014. Epub 2022 Oct 21. Int J Radiat Oncol Biol Phys. 2023. PMID: 36280151 Clinical Trial.
Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
Park JE, Hong KS, Choi SH, Lee SY, Shin KC, Jang JG, Kwon YS, Park SH, Choi KJ, Jung CY, Eom JS, Kim S, Seol HY, Kim J, Kim I, Park JH, Kim TH, Ahn JH. Park JE, et al. Among authors: park jh, park sh. Clin Lung Cancer. 2024 Jun;25(4):354-364. doi: 10.1016/j.cllc.2024.02.006. Epub 2024 Feb 17. Clin Lung Cancer. 2024. PMID: 38503590
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.
Kim I, Choi SH, Lee SY, Yoo SS, Park JE, Shin KC, Jang JG, Hong KS, Kwon YS, Park SH, Choi KJ, Jung CY, Kim MH, Kim SH, Seol HY, Kim J, Park JH, Kim TH, Eom JS, Ahn JH. Kim I, et al. Among authors: park jh, park je, park sh. Anticancer Res. 2024 Oct;44(10):4505-4516. doi: 10.21873/anticanres.17279. Anticancer Res. 2024. PMID: 39348962
11,125 results
You have reached the last available page of results. Please see the User Guide for more information.